Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use. For more details, see the full press release at https://ibn.fm/QOWWK.
This announcement is significant because it marks a tangible step toward making GelrinC available to European patients. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. According to Regentis, the product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The European launch could provide a new treatment option for patients with knee cartilage lesions, potentially reducing the need for more invasive surgeries.
The training program at Humanitas Research Hospital, a renowned medical center, underscores Regentis’ commitment to ensuring surgeons are proficient with the GelrinC implant. As the company expands training to other European centers, it will build a network of expertise that could accelerate adoption. For Regentis, successful commercialization in Europe could also pave the way for future regulatory filings in other regions, including the U.S., where the unmet need for off-the-shelf cartilage repair solutions is substantial.
Investors and industry observers will watch the training rollout closely, as it provides early indications of market reception. The forward-looking statements in the announcement highlight risks and uncertainties, including those detailed in the company’s SEC filings, which caution against undue reliance on projections. Nevertheless, the initiation of surgeon training represents a concrete milestone in Regentis’ strategy to bring GelrinC to market and address a significant orthopedic need.
